Amundi
KYMR icon

Amundi’s Kymera Therapeutics KYMR Stock Holding History

Amundi’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Hold
2,988
– – ﹤0.01% 1797
2026
Q1 		$249K Buy
+2,988
New +$237K ﹤0.01% 1812
2025
Q2 		– Sell
-40
Closed -$948 – 1947
2025
Q1 		$948 Buy
40
+21
+111% +$766 ﹤0.01% 2044
2024
Q4 		$770 Buy
+19
New +$858 ﹤0.01% 2057
2023
Q4 		– Sell
-1,642
Closed -$20.7K – 2037
2023
Q3 		$20.7K Hold
1,642
– – ﹤0.01% 1930
2023
Q2 		$38.7K Hold
1,642
– – ﹤0.01% 1920
2023
Q1 		$49K Hold
1,642
– – ﹤0.01% 1888
2022
Q4 		$49.1K Buy
+1,642
New +$43.8K ﹤0.01% 1703

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Amundi's KYMR Position: Q2 2026 in Review

Amundi held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 2,988 shares worth $343K. The position accounts for ﹤0.01% of the portfolio, ranked #1797.

Amundi first reported a position in KYMR in Q4 2022 and has held it in 8 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Amundi held 2,988 shares of Kymera Therapeutics worth $343K as of Q2 2026.
  • Amundi left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1797 holding.
  • Amundi first reported a position in Kymera Therapeutics in Q4 2022 and has held it in 8 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.